Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on
vascular inflammation following 24 weeks of dosing.
Phase:
Phase 2
Details
Lead Sponsor:
Tallikut Pharmaceuticals, Inc.
Collaborators:
Icahn School of Medicine at Mount Sinai Massachusetts General Hospital Montreal Heart Institute University of Massachusetts, Worcester Winthrop University Hospital